Literature DB >> 2844546

The TSH, T4, T3 and prolactin responses to consecutive infusions of a potent and stabilized thyrotrophin releasing hormone analogue, RX77368, in man.

D J Eckland1, S L Lightman.   

Abstract

The endocrine manifestations of a stabilized thyrotrophin releasing hormone (TRH) analogue, RX77368, have been investigated in six male volunteers. Infusions were given on two occasions, with a 5-day interval between infusions. On the second exposure to RX77368, there was a significant reduction in the TSH response, despite normal basal T3 and T4 levels, while the response of prolactin to RX77368 was unaltered. Domperidone administered during the infusion of RX77368 caused a further elevation of prolactin levels, whilst TSH levels were unchanged. This study shows the differential regulation of thyrotrophs and lactotrophs in response to stimulation by a TRH analogue, and shows, for the first time, down-regulation of the TSH response in vivo, in the presence of normal peripheral thyroid hormone levels. The T3 response to infusions of RX77368 was less than to a bolus injection of TRH, despite a greater TSH response to the analogue, suggesting impaired biological activity of TSH released in response to an infusion of the analogue.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844546     DOI: 10.1111/j.1365-2362.1988.tb01031.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  2 in total

1.  The effects of repeated administration of a long acting TRH analogue (RX77368), on TSH, T4, T3 and prolactin in patients with motor neuron disease.

Authors:  D J Eckland; H Modarres-Sadeghi; S L Lightman; R J Guiloff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-09       Impact factor: 10.154

Review 2.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.